Purpose Studies in cancer patients with venous thromboembolism suggested that low
molecular weight heparin may prolong survival. In a double-blind study, we evaluated the …

Purpose Earlier studies showed that low molecular weight heparin significantly prolongs the
survival of a wide variety of patients with cancer without venous thromboembolism. This …

OBJECTIVE To prospectively assess whether low-molecular-weight heparin (LMWH)
provides a survival benefit in patients with advanced cancer. PATIENTS AND METHODS …

Background: Low‐molecular‐weight heparins (LMWH) have an antitumor effect in vitro and
in experimental animal models of malignancy. Retrospective data suggest that it might …

Heparin is a familiar anticoagulant drug with properties that may impede tumor growth; it
modifies properties of cells that contribute to malignant dissemination such as angiogenesis …

Background Tumors may exploit the coagulation system to enhance the survival and
dissemination of cancer cells. Some studies have suggested that heparin and low molecular …

The influence of unfractionated heparin (UFH) and other anticoagulants on the spread of
cancer has been reported since the early 1960s. 1 However, clinical studies investigating …

Purpose Experimental studies and indirect clinical evidence suggest that low molecular
weight heparins may have antineoplastic effects. We investigated the influence of a low …

Purpose Venous thromboembolism (VTE) is common in cancer patients. Evidence has
suggested that low molecular weight heparin (LMWH) might improve survival in patients with …

Malignant conditions are frequently associated with a hypercoaguable state, with recurrent
thrombosis due to the impact of cancer cells and chemotherapy or radiotherapy on the …